Ibudilast

DB05266InvestigationalSmall molecule

Ibudilast is an anti-inflammatory and neuroprotective oral agent which shows an excellent safety profile at 60 mg/day and provides significantly prolonged time-to-first relapse and attenuated brain volume shrinkage in patients... Ibudilast is currently in development in the U.S.

Mechanism: Ibudilast has mechanisms that include anti-inflammatory effects, such as phosphodiesterase inhibition, and neuroprotective effects, such as inhibition of nitric oxide synthesis and reduction in reactive oxygen species.
Curator reviewed
Primary indication: For the treatment of multiple sclerosis, asthma, and cerebrovascular disease.Curator reviewed
Formula / weight: C₁₄H₁₈N₂O · 230.3055 g/mol (avg)
Code names: AV-411 · BRN 0656579 · MN-166

Resolves to

Compound

UNIIM0TTH61XC5CAS50847-11-5ChEMBLCHEMBL19449ChEBI31684PubChem3671

Clinical / RWD

ATCR03DC04PharmGKBPA165958351

Structure

InChIKeyZJVFLBOZORBYFE-UHFFFAOYSA-NSMILESCC(C)C(=O)C1=C2C=CC=CN2N=C1C(C)C

Targets

O76074PDE5AQ9Y233PDE10AP27815PDE4AQ07343PDE4BQ08493PDE4CQ14432PDE3AQ08499PDE4D

What you can answer from here — as of June 15, 2026

8Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

718Drug interactionsStructured to mechanism, not free text

23Clinical trialsPhase, status and sponsor resolved per trial

1ATC codeIncluding every combination product, plus 15 drug categories

34+ReferencesStructured and connected to the statements they support

Which drugs share a target with Ibudilast, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Log In Paid Account Log In